Acne vulgaris
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 35 years, without cognitive impairment; 2. Diagnosed with acne vulgaris, which accorded with Pillsbury grading III-IV; 3. After fully explaining the purpose and content of this clinical trial (including subjects' compliance, etc.), voluntarily signed an informed consent form to participate in the clinical trial on the basis of full understanding.
Exclusion criteria
Exclusion criteria: 1. Those who are known to be allergic to experimental drugs or related drugs; 2. Those who have received acne treatment (ALA-PDT, antibiotics, fruit acid, etc.) within 3 months before entering the group; 3. Those who take phototoxic or photosensitive drugs within 8 weeks before entering the group (such as tetracycline antibiotics, sulfonamides, phenothiazines, etc.); 4. Patients with facial diseases that may affect the evaluation of curative effect (skin photosensitivity, porphyria, other photodermatosis, etc.); 5. Participate in any drug clinical trial within 1 month before this trial (as subjects); 6. Complicated with serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, etc.; 7. Patients with abnormal liver function, dyslipidemia or severe low immunity; 8. Scar physique; 9. Pregnant or lactating women, and subjects of childbearing age (including men) who refused to take appropriate contraceptive measures during the study; 10. Subjects with severe physical or mental illness that researchers believe may affect treatment, evaluation, or poor compliance with the study program.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction rate of lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain score;Scores of therapeutic reactions;Incidence of other side effects; | — |
Countries
China
Contacts
Shanghai Skin Disease Hospital